Therapy Areas: Inflammatory Diseases
REGENXBIO reports positive three-year durability data for surabgene lomparvovec in diabetic retinopathy
25 September 2026 - Biotechnology company REGENXBIO Inc (Nasdaq:RGNX) on Thursday announced positive long-term follow-up data from the Phase II ALTITUDE study of investigational surabgene lomparvovec ...
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
25 September 2026 - XtalPi (HKEX:2228), an AI- and robotics-driven drug and materials discovery company, announced on Thursday the submission of an Investigational New Drug (IND) application to the US...
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
22 September 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Tuesday it has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiop...
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
9 September 2026 - Altesa BioSciences, a clinical-stage pharmaceutical company focused on chronic lung diseases including COPD and asthma, announced on Tuesday new clinical data showing that its inves...
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administ...
Teva reports positive Phase 2a data for TEV '408 in celiac disease
2 September 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Wednesday reported positive top-line results from an ongoing Phase 2a study of TEV &...